Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.